Table 3.

Fluoroquinolones Withdrawn From US Market

Drug	Year Withdrawn	Reason for Withdrawal
Temafloxacin	1992	Hypoglycemia in elderly patients as well as a constellation of multisystem organ involvement characterized by hemolytic anemia, frequently associated with renal failure, markedly abnormal liver tests, and coagulopathy
Trovafloxacin	1999	Marketing authorization suspended due to hepatic events
Gatifloxacin	2006	Dysglycemia (hypoglycemia and hyperglycemia)
Grepafloxacin	2007	Voluntarily withdrawn, manifested as QTc interval prolongation on the electrocardiogram, which could put patients at risk of torsade de pointes